Spectral Diagnostics (EDTXF) to Release Quarterly Earnings on Thursday

Spectral Diagnostics (OTCMKTS:EDTXF) is expected to post its results before the market opens on Thursday, March 26th. Analysts expect Spectral Diagnostics to post earnings of ($0.0073) per share and revenue of $0.5410 million for the quarter.

Spectral Diagnostics Trading Up 3.7%

OTCMKTS EDTXF opened at $0.95 on Tuesday. The firm has a market capitalization of $277.93 million, a P/E ratio of -8.64 and a beta of 0.04. The firm’s fifty day moving average price is $0.97 and its two-hundred day moving average price is $1.00. Spectral Diagnostics has a 1 year low of $0.47 and a 1 year high of $1.31.

About Spectral Diagnostics

Spectral Medical Inc focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.